Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Remdesivir
- drug: Cyclosporine
- drug: Imatinib Mesylate
- drug: Dexamethasone
- drug: Cenicriviroc
- drug: Icatibant
- drug: Apremilast
- biological: dornase alfa
- drug: Celecoxib
- drug: Famotidine
- biological: IC14
- drug: Aviptadil
- biological: narsoplimab
- drug: Cyproheptadine
Eligibility
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask
delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2
infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during
hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic
conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on
dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Remdesivir
- drug: Cyclosporine
- drug: Imatinib Mesylate
- drug: Dexamethasone
- drug: Cenicriviroc
- drug: Icatibant
- drug: Apremilast
- biological: dornase alfa
- drug: Celecoxib
- drug: Famotidine
- biological: IC14
- drug: Aviptadil
- biological: narsoplimab
- drug: Cyproheptadine
Eligibility
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask
delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2
infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during
hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic
conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on
dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Remdesivir
- drug: Cyclosporine
- drug: Imatinib Mesylate
- drug: Dexamethasone
- drug: Cenicriviroc
- drug: Icatibant
- drug: Apremilast
- biological: dornase alfa
- drug: Celecoxib
- drug: Famotidine
- biological: IC14
- drug: Aviptadil
- biological: narsoplimab
- drug: Cyproheptadine
Eligibility
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask
delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2
infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during
hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic
conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on
dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Remdesivir
- drug: Cyclosporine
- drug: Imatinib Mesylate
- drug: Dexamethasone
- drug: Cenicriviroc
- drug: Icatibant
- drug: Apremilast
- biological: dornase alfa
- drug: Celecoxib
- drug: Famotidine
- biological: IC14
- drug: Aviptadil
- biological: narsoplimab
- drug: Cyproheptadine
Eligibility
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask
delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2
infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during
hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic
conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on
dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Remdesivir
- drug: Cyclosporine
- drug: Imatinib Mesylate
- drug: Dexamethasone
- drug: Cenicriviroc
- drug: Icatibant
- drug: Apremilast
- biological: dornase alfa
- drug: Celecoxib
- drug: Famotidine
- biological: IC14
- drug: Aviptadil
- biological: narsoplimab
- drug: Cyproheptadine
Eligibility
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask
delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2
infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during
hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic
conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on
dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Remdesivir
- drug: Cyclosporine
- drug: Imatinib Mesylate
- drug: Dexamethasone
- drug: Cenicriviroc
- drug: Icatibant
- drug: Apremilast
- biological: dornase alfa
- drug: Celecoxib
- drug: Famotidine
- biological: IC14
- drug: Aviptadil
- biological: narsoplimab
- drug: Cyproheptadine
Eligibility
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask
delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2
infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during
hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic
conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on
dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting